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ABSTRACT: A photoactivated ruthenium(II) arene complex has been conjugated to two receptor-binding peptides, a dicarba ana-
logue of octreotide and the RGD tripeptide. These peptides can act as “tumor targeting devices” since their receptors are overex-
pressed on the membranes of tumor cells. Both ruthenium-peptide conjugates are stable in aqueous solution in the dark, but upon 
irradiation with visible light, the pyridyl-derivatized peptides were selectively photodissociated from the ruthenium complex, as in-
ferred by UV-vis and NMR spectroscopy. Importantly, the reactive aqua species generated from the conjugates, [(η6-p-
cym)Ru(bpm)(H2O)]
2+, reacted with the model DNA nucleobase 9-ethylguanine, as well as with guanines of two DNA sequences, 
5´dCATGGCT and 5´dAGCCATG. Interestingly, when irradiation was performed in the presence of the oligonucleotides, a new ru-
thenium adduct involving both guanines was formed as a consequence of the photo-driven loss of p-cymene from the two monofunc-
tional adducts. The release of the arene ligand and the formation of a ruthenated product with a multidentate binding mode might 
have important implications for the biological activity of such photoactivated ruthenium(II) arene complexes. Finally, photoreactions 
with the peptide-oligonucleotide hybrid, Phac-His-Gly-Met-linker-p5´dCATGGCT, also led to arene release and to guanine adducts 
including a GG chelate. The lack of interaction with the peptide fragment confirms the preference of such organometallic ruthe-
nium(II) complexes for guanine over other potential biological ligands such as histidine or methionine amino acids. 
Introduction. Cisplatin and its second-generation derivatives 
(carboplatin and oxaliplatin) are successful drugs for the treat-
ment of some types of cancer.1 However their use is sometimes 
accompanied by severe toxic side-effects together with the de-
velopment of resistance in cells, and their limited spectrum of 
activity. This has stimulated the search for other innovative 
metal-based anticancer drugs. The main challenge concerns the 
improvement of targeting strategies either by designing transi-
tion metal complexes with ligands that might improve cellular 
uptake and tumor selectivity, or by using non-toxic pro-drugs 
whose activity might be triggered within cancer cells.2 There are 
several examples of metal complexes that have been conjugated 
to carrier molecules such as folate, delivery peptides or nanopar-
ticles.3 Although the covalent attachment to a biological vector 
is expected to have a positive effect on the delivery of the metal-
based drug to cancer cells, it must also be borne in mind that 
the carrier molecule might affect activity, especially in those 
cases where the final target is a biomacromolecule (e.g. DNA, 
RNA or proteins).  
Photochemical activation of a metal anticancer pro-drug is a 
promising strategy since its activity can be triggered by irradia-
tion directly within the tumor.4  Spatial and temporal control 
over release of the active species should result in greater selectiv-
ity and, consequently, in a reduction of side-effects since the 
cytotoxicity of the anticancer agent will be limited to the irradi-
ated area. For example, octahedral diazido platinum(IV) com-
pounds are potently cytotoxic towards cancer cells only when 
irradiated with light and can form Pt-nucleotide DNA cross-
links.5  
In the case of organometallic complexes, we have recently de-
scribed a pseudooctahedral piano-stool Ru(II) arene complex, 
[(η6-p-cym)Ru(bpm)(py)]2+, that can also be activated by visible 
light.6 Aqueous solutions of the complex are stable in the dark 
but photodissociation of the Ru-pyridine bond occurs under 
irradiation with visible light, so providing a mechanism for 
activation.7 In addition, the ability of the reactive aquated spe-
cies to bind to 9-ethylguanine suggests a potential route to bind 
to biomolecules such as DNA nucleobases. Since the cytotoxic-
ity of some organometallic Ru(II) complexes has been correlated 
with DNA binding, [(η6-p-cym)Ru(bpm)(py)]2+ represents a can-
didate in the search for new photoactive metal-based anticancer 
drugs.8 Here we propose a strategy for improving selectivity 
against cancer cells based on the covalent attachment of a deliv-
ery peptide to the ruthenium(II) complex through the pyridine 
ligand. As shown in Scheme 1, photolysis with visible light 
could initiate ligand dissociation and, consequently, the separa-
tion of both entities with the concomitant generation of the 
activated aqua species 1. It is expected that the peptide frag-
ment will improve the aqueous solubility and the cellular up-
take of the ruthenium-based drug whilst maintaining its 
mechanism of action, via light-induced ligand release and sub-
sequent interaction with biomolecules such as DNA. This strat-
egy would generate ruthenium-based pro-drugs with a double 
mechanism of selectivity: the specificity brought by the delivery 
peptide and the photochemical activation of the ruthenium 
complex which will would provide control of the fundamental 
step in the mechanism of action of such Ru(II) compounds. 
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Scheme 1. Structure of the conjugates synthesized and sche-
matic representation of the photodissociation process 
 
On this basis, we selected two relevant receptor-binding pep-
tides that are expected to act as “tumor targeting devices”. On 
the one hand, we have focused on a peptide containing the 
RGD (Arg-Gly-Asp) sequence to target tumour endothelial cells 
over healthy cells through binding to the αVβ3 and αVβ5 in-
tegrins.9 These cell surface receptors play a predominant role in 
tumour-induced angiogenesis and are overexpressed on certain 
tumour cells during tumour growth and metastasis. On the 
other hand, we have chosen octreotide, a potent cyclooctapep-
tide agonist of the endocrine hormone somatostatin, that dis-
plays high affinity and specificity towards the sst2 receptor sub-
type located in the cell membrane.10 The fact that somatostatin 
receptors and, in particular sst2, are overexpressed in various 
types of malignant cells, makes this peptide suitable for the 
specific delivery of metal-based anticancer drugs.11 Indeed, the 
overexpression of the receptors for both peptides in tumors has 
been exploited to deliver cytotoxic agents in tumour cells as well 
as for molecular imaging purposes by delivering radionu-
clides.3c,e,9b,12  
We report the synthesis and characterization of two novel 
conjugates, 2 and 3 (Scheme 1), in which a photoactivated or-
ganometallic ruthenium(II) complex is covalently bound to two 
receptor-binding peptides, the dicarba analogue of octreotide 
and the RGD tripeptide, respectively. We have investigated the 
effect of conjugation on photoactivation of the complexes, and 
competitive photo-induced reactions with DNA and peptides as 
potential targets. Our studies reveal not only a selectivity in 
ruthenation of target sites but also the photo-induced forma-
tion of multidentate coordination sites on ruthenium. 
 
Results and Discussion 
Synthesis of the ruthenium-peptide conjugates. On the basis 
of our previous studies on the synthesis of platinum(II)-
octreotide conjugates,3e we choose a dicarba analogue of octreo-
tide in which the disulfide bond is replaced by the CH2–CH2 
linkage isostere. This modification does not substantially alter 
the binding affinity toward the sst2 receptor but increases its 
stability in the reductive cellular environment.13 For the synthe-
sis of the conjugates 2 and 3, a stepwise solid-phase approach 
was chosen since it allows the regioselective introduction of the 
ruthenium fragment at the N-terminal end of the peptide. This 
strategy has been applied successfully to the synthesis of several 
conjugates between peptides and coordination or organometal-
lic complexes.3e,3i,14 In our case, instead of synthesizing a ruthe-
nium complex bearing a carboxylic acid function anchored at 
the pyridine ligand, we decided to incorporate 4-pyridyl acetic 
acid at the N-terminal end of the peptide. This ligand allows 
assembly of the desired ruthenium complex by displacement of 
the chlorido ligand in [(η6-p-cym)Ru(bpm)(Cl)]+ or aqua ligand 
in the hydrolysed complex 1 (Scheme 2). A polyethyleneglycol 
spacer was introduced between the pyridine ligand and the 
peptide sequence so the ruthenium complex does not interfere 
with the binding of the peptide pharmacophore and to improve 
the aqueous solubility of the conjugate. 
First, both peptides were manually assembled on a Rink am-
ide resin using standard Fmoc-tBu methodology. The suitably-
protected Fmoc-amino acids were incorporated using HATU in 
the presence of DIPEA (octreotide) or DIPC/HOBt (RGD) as 
coupling reagents. In the case of octreotide, Fmoc-protected 
threoninol functionalized as the p-carboxybenzaldehyde acetal 
was first attached to the solid support and the two cysteines in 
the octreotide sequence were replaced by allyl glycine residues. 
On-resin ring-closing metathesis with second-generation Grubbs 
catalyst under microwave irradiation followed by the hydro-
genation of the double bond using Wilkinson’s catalyst 
afforded the cyclic saturated dicarba analogue of octreotide 
bound to the resin.3e,13 Finally, after the incorporation of the 
Fmoc-protected polyethyleneglycol linker into the RGD- and 
octreotide-bound resins, 4-pyridyl acetic acid hydrochloride was 
coupled using HATU (Scheme 2).  
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Our initial strategy for synthesis of the ruthenium conjugate 
involved coordination to the pyridine ligand followed by acidic 
treatment with TFA to cleave the conjugate from the resin and 
to deprotect the amino acid side chains (Scheme 2). The com-
plex [(η6-p-cym)Ru(bpm)(Cl)]+ as well as its aqua adduct 1 were 
reacted under a variety of conditions in the dark (DMF, 
DMF/EtOH or DCM at 60ºC or under microwave irradiation) 
with both pyridyl-derivatized peptide-bound resins to generate 
the desired photoactivatable complex. Unfortunately, after 
treatment of the metal-peptide-bound resins either with a cock-
tail of TFA/H2O/TIS 95:2.5:2.5 or with TFA/H2O 95:5, nei-
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ther ruthenium conjugate 2 nor 3 were identified in the crude 
products, as inferred by reversed-phase HPLC analysis and ESI 
and MALDI-TOF mass spectrometry. In all cases, the pyridyl-
derivatized peptides 4 and 5 (Scheme 1) were identified as the 
main products together with the ruthenium complex 1, which 
suggested that the complex was assembled on the solid-phase 
but that the pyridyl ligand-linker-peptide dissociated during the 
acidic treatment. This result prompted us to assemble the 
photoactivatable ruthenium complex in solution (Scheme 2). 
The required pyridyl-derivatized peptides, 4 and 5, were iso-
lated from the peptide-bound resins by treatment with a 
TFA/H2O/TIS 95:2.5:2.5 cocktail, and purification was carried 
out by semipreparative reversed-phase HPLC. The pyridyl-
derivatized octreotide 4 was dissolved in Milli-Q water (ca 10 
mM) and the pH was adjusted to 6.5 by addition of a few drops 
of a 10 mM aqueous solution of NaOH. Then, the reaction 
flask was protected from light with aluminium foil and the re-
quired amount of a solution of the aquated ruthenium complex 
1 (4 mol eq) in a 1:1 mixture of H2O/MeOH was added drop-
wise for 5 min. After 72 h at 60ºC, reversed-phase HPLC analy-
sis of the crude revealed the formation of a new product which 
was isolated by semipreparative HPLC and characterized by 
high-resolution ESI MS as the desired conjugate 2. The same 
procedure was followed for the synthesis of the conjugate 3 
from the pyridyl-derivatized RGD peptide 5. 
Photoactivation of the ruthenium-peptide conjugates. Next 
we studied the photochemical properties of the ruthenium-
peptide conjugates 2 and 3 to assess how the covalent linkage of 
the peptides to the pyridine ligand affects the photoactivation 
of the ruthenium complex. First, we tested the stability of 2 and 
3 in the dark (see Figure S-5). As found previously for [(η6-p-
cym)Ru(bpm)(py)]2+,6 NMR spectra revealed that both peptide-
ruthenium conjugates are completely stable in aqueous solution 
in the dark (first at 4ºC for 24 h, then at 37ºC for 6 h).  
The monitoring of the photoactivation processes for 2 and 3 
was carried out by UV-vis and NMR spectroscopy. In both 
cases, an aqueous solution of the conjugate was irradiated with 
blue visible light (420 nm lamps) in a photo-reactor at 37ºC and 
the UV-Vis spectra and the NMR spectra were recorded at dif-
ferent times. As shown in Figure 1, the ruthenium-octreotide 
conjugate 2 showed essentially the same behaviour to that of 
[(η6-p-cym)Ru(bpm)(py)]2+,6 which indicates that the covalent 
attachment of the cyclic peptide to the pyridine ligand does not 
affect the photoactivity properties of the metal complex. 
The electronic spectrum of 2 displays maxima at 256 nm, 
286 nm (shoulder) and 367 nm. The presence of an isosbestic 
point at 309 nm is consistent with the formation of a single 
photoproduct. 1H NMR spectra recorded at different times 
during the photolysis confirm the release of the octreotide-
functionalized pyridine 4 and the formation of the reactive 
aqua species [(η6-p-cym)Ru(bpm)(H2O)]2+ (1). Resonances for the 
metal fragment of 1 and 2 were assigned by reference to previ-
ous work on the pyridine complex.6 No significant difference 
was observed in the rate and extent of photo-induced ligand 
release compared to the derivative [(η6-p-cym)Ru(bpm)(py)]2+ 
under the same light irradiation conditions. Similar results were 
obtained with conjugate 3 (see Figures S-7 and S-8): the 
photorelease of the tripeptide-functionalized pyridine 5 was 
observed when a solution of 3 was irradiated with blue light at 
37ºC.  
Interestingly, no formation of peptide-metal complex adducts 
during light irradiation of either conjugate was evident by 
NMR. Such behavior is not surprising since neither octreotide 
nor the tripeptide sequence contain residues with proven ru-
thenium-binding properties (e.g. Met, His or Cys; see below). 
 
Figure 1. Photolysis (λmax = 420 nm, 37ºC) of 2 in aqueous solu-
tion followed by (A) UV-vis and (B) 1H NMR spectroscopy. UV-vis 
spectra were collected at t = 0 min (black curve), every 20 min of 
irradiation for the first hour and every 30 min for the next 7 h; 1H 
NMR spectra were collected at t = 0 min (B, top) and every 30 min 
of irradiation up to 4 h. Assignments: blue = 2, green = 1, ■ = bpm, 
▲ = py, ● = p-cym. Resonances of the released pyridine functional-
ized with the octreotide peptide are indicated with orange ▲. 
DNA ruthenation by photoactivated conjugates. DNA is a 
potential target for cytotoxic piano-stool Ru(II) arene com-
plexes.8 Therefore we investigated the ability of photoactivated 
ruthenium-peptide conjugates to ruthenate both the model 
DNA nucleobase 9-ethylguanine (9-EtG) and two short DNA 
sequences, 5´dCATGGCT and 5´dAGCCATG, under visible 
light irradiation. First 9-ethylguanine was added to an irradiated 
(480 min) solution of 2 (3:1 mol ratio) and incubated at 37ºC. 
As shown in Figure 2, 1 binds 9-EtG over time to give a 1-9-EtG 
adduct. A new set of signals appeared in the aromatic region 
and a 2D NOESY cross peak between the H8 of the coordi-
nated 9-EtG and the 2,2'-CH bpm proton was detected (see also 
Figure S-6). Similar results were obtained for the RGD conju-
gate 3. The reactive aqua species 1 photoreleased from the 
RGD-functionalized pyridine also coordinated to 9-EtG (see 
Figure S-9). These results demonstrate that functionalization of 
the pyridine ligand in the ruthenium(II) arene complex [(η6-p-
cym)Ru(bpm)(py)]2+ with small-to-medium-sized peptides does 
not adversely affect the photoactivation process nor the interac-
tion of the photoreleased reactive aqua species 1 with a model 
G nucleobase. 
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Figure 2. Reaction between 9-EtG and an irradiated solution (λmax 
= 420 nm, 240 min, 37ºC) of octreotide conjugate 2. (A) Aromatic 
region of the 1H NMR spectrum during the course of the reaction. 
Spectra were collected at t = 0 min (A, top) and every 60 min up to 
7 h. (B) 2D 1H-1H NOESY NMR spectrum after 480 min of reac-
tion. Green = 1, red = 1-9-EtG adduct; ■ = bpm, ▲ = py, ● = p-
cym. Resonances of the released pyridine functionalized with the 
octreotide peptide are indicated with orange ▲ and coordinated 9-
EtG (H8) with red ♦. 
Next we studied the short synthetic oligonucleotide 
5´dCATGGCT which contains a GpG sequence, the target for 
the anticancer drug cisplatin.1 This DNA fragment gives the 
expected platinum 1,2-intrastrand GG chelates upon reaction 
either with cisplatin, [Pt(en)Cl2] or the dichloroplatinum(II) 
conjugate of a dicarba analogue of octreotide.3e,15  
First, 5´dCATGGCT was added to an irradiated (8 h) solu-
tion of conjugate 2 (5:1 mol ratio) and incubated overnight. 
Reversed-phase HPLC analysis with on-line UV detection 
showed the presence of two new peaks with higher retention 
time than the parent oligonucleotide (Rt = 18.3 and 19.1 min; 
relative ratio 0.85:1, respectively; see Figure 3), attributable both 
to the hydrophobicity of the ruthenating fragment, {(η6-p-
cym)Ru(bpm)}2+, as well as to the position of the ruthenation in 
the sequence. High resolution ESI and MALDI-TOF MS analy-
sis of the two products confirmed the formation of isomeric 
ruthenated DNA adducts in which a single ruthenium frag-
ment, {(η6-p-cym)Ru(bpm)}2+, was coordinately bound to the 
DNA chain (6a-b) (Scheme 3). The position of the ruthenium 
adduct was determined by MS analysis of the products after 
enzymatic digestion with 5´- and 3´-exonucleases (bovine spleen 
and snake venom phosphodiesterases, respectively).16 As ex-
pected, the aqua ruthenium complex reacted exclusively with 
both guanines, thus paralleling the reactivity towards the model 
nucleobase 9-EtG. The high affinity of similar ruthenium(II) 
arene complexes, such as [(η6-p-cym)Ru(en)Cl]+, for the N7 posi-
tion of guanine has been observed previously for different oli-
gonucleotide sequences.17 This strong preference for the N7 site 
of guanine over the other DNA nucleobases has also been 
demonstrated in the case of the aqua complex [(η6-
benzene)Ru(en)(OH2)]
2+ by using computation either in the gas 
or in aqueous solution.18  
As a control, the reaction between 5´dCATGGCT and [(η6-p-
cymene)Ru(bpm)(OH2)]
2+ was carried out in aqueous solution 
to confirm that the latter species is responsible for the forma-
tion of the monofunctional ruthenium adducts. Indeed, only 
6a and 6b were detected by reversed-phase HPLC analysis in a 
similar ratio as in the previous experiment. In addition, no 
reaction was observed when conjugate 2 and 5´dCATGGCT 
were incubated for 16 h at ambient temperature in the dark 
(Figure S-10), which suggests that direct displacement of the 
pyridyl-derivatized peptide by guanines from the DNA cannot 
readily take place. These results confirm that photoreleased 
aqua complex 1 is the ruthenating species and that the peptide 
does not interfere in the DNA ruthenation step.  
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Figure 3. Reversed-phase HPLC traces for (A) the reaction 
between 5´dCATGGCT and an irradiated solution of conjugate 
2 (8 h, 37ºC) after a further 15 h at ambient temperature and 
(B) the in situ reaction between 5´dCATGGCT and conjugate 2 
after 9 h of irradiation at 37ºC. (C) Absorption spectra of the 
isolated adducts 6a (green), 6b (black) and 6c (red). The inset 
shows an expansion of the 300-700 nm region. 
It is interesting that 1 is able to ruthenate both guanines of 
the GG sequence in the oligonucleotide, which is a different 
trend from that previously described for monofunctional plati-
num(II) complexes. For example, {Pt(dien)}2+, a model for mon-
ofunctional adducts of cisplatin, exclusively reacts with the 5’G 
nucleobase in the 5´dCATGGCT sequence.15 In addition, it 
seems that there is no preference for any of the guanines in the 
GG-containing oligonucleotide. This is also a different trend 
compared to cisplatin, for which it has been reported that there 
is a slight preference for 3’G monofunctional adducts in GG 
sequences.19 
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Once the ability of photoreleased 1 to ruthenate DNA had 
been demonstrated, we investigated whether the monofunc-
tional adducts 6a (G5-Ru) and 6b (G4-Ru) would also be formed 
when conjugate 2 was photoactivated in the presence of the 
oligonucleotide. Thus, an aqueous solution of conjugate 2 to-
gether with 5 mol eq of 5´dCATGGCT was irradiated with blue 
light at 37ºC for 9 h. Interestingly, reversed-phase HPLC analy-
sis showed the presence of a new peak (Rt = 18.6 min; see Fig-
ure 3B) together with two peaks corresponding to adducts 6a 
and 6b. The UV-vis absorption spectrum of this new compound 
(6c) contained some different features to those of 6a and 6b 
(Figure 3C), notably the appearance of a broad band near 550 
nm. These changes in the absorption spectrum suggested that 
the environment of the metal might had been substantially 
modified. 
To our surprise, HR ESI and MALDI-TOF MS analysis of the 
new product 6c revealed the formation of a DNA adduct in 
which the p-cymene ligand had been displaced from ruthenium 
and the single ruthenium fragment, {Ru(bpm)}2+, was bound to 
the oligonucleotide. The fact that this product is formed only 
when the mixture of the conjugate and the oligonucleotide is 
continuously irradiated suggests that the loss of the p-cymene 
ligand is triggered by irradiation with visible light and perhaps 
driven by formation of a GG chelate. It is important to note 
that NMR data from the photoactivation experiments with 
conjugates 2 and 3 appear to rule out the possibility that the 
loss of the arene ligand takes place from the photoreleased aqua 
species 1 as a consequence of the irradiation. Therefore, we 
hypothesize that 6c is generated from both monofunctional 
ruthenium adducts (6a and 6b) and that the formation of a 
more stable adduct (6c) is the driving force of the photo-
induced release of p-cymene. The UV-vis spectra of this com-
pound (Figure 3C) is in good agreement with the loss of the 
arene ligand.  
Two control experiments confirmed this hypothesis. First, all 
three adducts were obtained when a mixture of 5´dCATGGCT 
and [(η6-p-cymene)Ru(bpm)(OH2)]
2+ was irradiated at 37ºC for 7 
h (Figure S-11). Second, adduct 6c was generated when isolated 
monofunctional ruthenium adducts (6a-b) were photolysed. 
Interestingly, a mixture of the three adducts was always ob-
tained from each monofunctional adduct upon irradiation but 
adduct 6c remained unaltered (Figure S-12). These results con-
firm the higher stability of adduct 6c compared to that of 6a-b. 
Hence, continuous in situ irradiation of monofunctional 
ruthenated adducts triggers either deruthenation to regenerate 
the DNA strand or the release of the p-cymene ligand to give 
the most stable adduct, 6c. These observations are also in good 
agreement with MS results since the ionization conditions em-
ployed during MALDI-TOF MS analysis caused a large amount 
of ligand loss (both p-cymene and bpm) from adducts 6a and 6b 
in comparison with that observed for adduct 6c. However, no 
significant loss of the ligands was observed during HR ESI MS 
analysis (see Figures S-13-S-16).  
In order to determine the position of the ruthenating frag-
ment {Ru(bpm)}2+ in the oligonucleotide chain, 6c was submit-
ted to enzymatic digestion with exo- and endo-nucleases. MS 
analysis after treatment with 5´ and 3´ phosphodiesterases as 
well as with nuclease S1 confirmed that G4 and G5 are involved 
in ruthenium coordination (Scheme 3).  
 
 
 
Scheme 3. Contrasting pathways for photo-induced reactions of 
octreotide conjugate 2 with 5
′
dCATGGCT. Left branch: pre-
irradiated followed by addition of the oligonucleotide. Right 
branch: irradiation of a mixture of 2 and the oligonucleotide. 
In the former only monofunctional adducts are formed, 
whereas the latter provides a pathway to bifunctional adducts 
via arene release 
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Since the irradiation of photoactivated ruthenium(II) arene 
complexes or their conjugates with carrier molecules, such as 
peptide conjugates 2 and 3, would be performed directly in the 
tumor, the formation of different types adducts with DNA such 
as 6a-c might have important biological consequences. For ex-
ample, it has been demonstrated that adducts formed when 
DNA is treated with [(η6-arene)Ru(en)Cl]+ are more difficult for 
enzymes to repair than the bifunctional adducts formed by cis-
platin.20 In the present case, besides typical monofunctional 
ruthenium adducts (6a-b), in situ irradiation triggers ruthena-
tion of DNA through the coordination of both guanines (6c). 
The release of the η6-arene ligand creates three potentially reac-
tive sites around the metal for interaction with DNA (or RNA) 
or other biomolecules (see below). As a consequence, this allows 
the formation of adducts with different structures compared to 
the typical monofunctional adducts formed by N,N-chelated 
ruthenium arene anticancer complexes or the classical 1,2-
intrastrand cross-links formed by square-planar cisplatin. This 
difference is likely to affect protein recognition of the ruthen-
ated lesions and hence their repair. 
Arene loss followed by binding to oligonucleotides and pro-
teins has been previously described for some classical ruthe-
nium(II) arene complexes, such as [(η6-p-cym)Ru(pta)Cl2] and 
[(η6-C6H5CF3))Ru(pta)Cl2].
21 In addition, we have previously 
found that the dinuclear complex [{(η6-indan)RuCl}2(µ-2,3-
dpp)]2+ undergoes indan loss via an oxygen-independent path-
way when irradiated at 365 nm UVA.22 However, analogous 
complexes containing p-cymene or hexamethylbenzene do not 
undergo arene loss upon irradiation, which can be attributed to 
their stronger donor character. The highly reactive ruthenium 
species created by the photoactivation of [{(η6-indan)RuCl}2(µ-
2,3-dpp)]2+ are also capable of forming both mono- and bifunc-
tional adducts with DNA. This is consistent with the fact that 
the release of p-cymene from 1 alone does not occur under irra-
diation with visible light but is photo-induced from the mono-
functional DNA adducts 6a-b to give 6c.  
Next we studied photo-induced ruthenation of an oligonu-
cleotide with two G bases in non-adjacent positions, 
5´dAGCCATG. Since the generation of non-classical ruthen-
 6 
ated adducts as a consequence of the photo-driven arene loss, 
such as 6c, might have important implications for the biological 
activity of photoactivated ruthenium(II) arene complexes be-
cause of their multidentate nature, we wondered whether the 
formation of these adducts is exclusively related to GG-
containing sequences in DNA or their formation might be 
more general.  
Again, irradiation with visible light of an aqueous solution of 
conjugate 2 together with 5´dAGCCATG led to three main 
products (7a-c) (see Figure S-17). HR MALDI-TOF MS analysis 
together with enzymatic digestion revealed that in the two 
products with higher retention times than the parent oligonu-
cleotide, 7b and 7c, the fragment {(η6-p-cym)Ru(bpm)}2+ was 
bound to G7 and G2, respectively (see Scheme 4 and Figure S-
18). Regarding product 7a, whose retention time is surprisingly 
lower than that of 5´dAGCCATG (14.0 min vs 15.2 min), HR 
MALDI-TOF MS analysis indicated that the p-cymene ligand 
had been lost, as previously found for 6c. Again, enzymatic 
digestion with 5´- and 3´-exonucleases revealed that both gua-
nines are involved in coordination to the ruthenating species, 
{Ru(bpm)}2+. In addition, a short treatment (10 min) of 7a with 
nuclease S1 afforded, among others, a product with an m/z 
ratio 18 units higher than that of the parent compound; this 
corresponds to the cleavage of a phosphodiester bond between 
both guanines with the subsequent addition of a water mole-
cule. The overall data from enzymatic digestions confirm the 
cyclic nature of 7a and that only guanines are involved in the 
coordination to the ruthenating fragment (Scheme 4). Hence, 
these results demonstrate again the high preference of the 
photoreleased species [(η6-p-cymene)Ru(bpm)(OH2)]
2+, for gua-
nines and that the phototriggered arene release allows their 
ligation via {Ru(bpm)}2+, even if they are located far from each 
other in a DNA sequence. The formation of such adducts is 
expected to alter DNA (or RNA) structure dramatically and, 
consequently, to interfere with cell repair mechanisms. 
 
Photo-induced reaction of ruthenium-octreotide conjugate 
with Phac-His-Gly-Met-linker-p5´dCATGGCT. As seen above, 
the aqua species 1 photoreleased from conjugate 2 is able to 
ruthenate DNA in situ. However, in a cell there would be com-
petition for binding from peptides and proteins. To investigate 
such competition we studied next reaction of a peptide-
oligonucleotide hybrid, Phac-His-Gly-Met-linker-
p5´dCATGGCT, in which the oligonucleotide sequence is cova-
lently attached to a tripeptide that contains the two residues 
most prone to form strong complexes with platinum and ru-
thenium compounds, methionine and histidine. This bioconju-
gate was synthesized using solid-phase procedures23 and it has 
been previously used in platination studies both with cisplatin 
and its inactive isomer transplatin.15,16a 
An aqueous solution of conjugate 2 and Phac-His-Gly-Met-
linker-p5´dCATGGCT (1 mol eq) was irradiated with visible 
light at 37ºC for 9 h. HPLC analysis revealed the formation of 
three main products (8a-c; see Scheme 4) with higher retention 
times than the parent bioconjugate (Rt = 16.0, 16.9 and 17.1 
min; relative ratio 0.95:0.75:1, respectively; see Figure 4). Simi-
larly to 5´dCATGGCT, the reaction between Phac-His-Gly-Met-
linker-p5´dCATGGCT and aqua adduct 1 afforded only two 
products, 8b and 8c. HR MALDI-TOF MS analysis of 8b and 
8c confirmed that the fragment {(η6-p-cym)Ru(bpm)}2+ was 
bound to the bioconjugate in both cases (see Figure S-19). 
 
Scheme 4. Formation of ruthenium adducts after irradiation of 
2 in the presence of the oligonucleotide (left) or the peptide-
oligonucleotide hybrid (right). 
2
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Reaction of 8b-c with an aqueous solution of H2O2 (5%) led 
to oxidation of the methionine thioether sulphur (to the sulfox-
ide, m/z 16 units higher)16 suggesting that the Met sulphur was 
unprotected and not ruthenated. In addition, removal of the 
fragment Phac-His-Gly-Met after digestion with pronase indi-
cated no coordination to the imidazole ring of the histidine 
residue.16 Finally, treatment with snake venom phosphodi-
esterase suggested that the G5 nucleobase was ruthenated in 8b 
and the G4 in 8c (fragments pCpT and pGpCpT were removed, 
respectively), thus reproducing the coordination pattern found 
in adducts 6a-b (see Schemes 3 and 4). 
 
 
Figure 4. Reversed-phase HPLC traces for the in situ reaction be-
tween (A) Phac-His-Gly-Met-linker-p5´dCATGGCT and conjugate 2 
after 9 h of irradiation at 37ºC, and (B) reaction between Phac-His-
Gly-Met-linker-p5´dCATGGCT and the ruthenium aqua adduct 1 
after 15 h at room temperature.  
 
Regarding adduct 8a, formed only during continuous irradia-
tion, HR MALDI-TOF MS analysis revealed the loss of the p-
cymene ligand which, as previously found with 5´dCATGGCT 
and 5´dAGCCATG, was a consequence of in situ irradiation 
with visible light. This is in good agreement with the UV-vis 
spectra of this compound in comparison with that of 8b-c (see 
Figure S-20). Again, treatment with H2O2 and digestion with 
pronase ruled out coordination of {Ru(bpm)}2+ to the peptide 
fragment. Enzymatic digestion with the 3´-exonuclease and 
with nuclease S1 revealed the formation of a chelate with both 
guanines (Scheme 4), thus confirming again the strong prefer-
ence of this ruthenium complex for these nucleobases. 
Two important conclusions can be drawn from these experi-
ments. First, the photoreleased aqua complex 1 does not react 
with the histidine nor methionine side chains in the peptide, 
but exclusively with the oligonucleotide portion to generate 
monofunctional adducts at both guanine nucleobases (8b-c). 
Second, in situ irradiation also induces the loss of the p-cymene 
ligand from the monofunctional adducts to generate a chelate 
(8a) in which {Ru(bpm)}2+ is bound to both guanines. Hence, 
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the behaviour of Phac-His-Gly-Met-linker-p5´dCATGGCT dem-
onstrates the preference of the photoactivated ruthenium(II) 
arene complex for DNA over peptides containing His N- and 
Met S-donor ligands. In addition, we observe photo-induced 
arene release from DNA monofunctional adducts and the for-
mation of a chelate involving two guanines (8a), equivalent to 
the course of the reaction observed for 5´dCATGGCT (6c) and 
5’dAGCCATG (7a). Perhaps surprisingly neither histidine nor 
methionine appear to bind to either of the two vacant coordi-
nation positions on the ruthenium(II) in 8a. This might be a 
consequence of steric hindrance because of the covalent at-
tachment between the peptide and the oligonucleotide chain. 
To check this possibility, we irradiated conjugate 2 in the pres-
ence of 5´dCATGGCT (1 mol eq) and the peptide Ac-His-Gly-
Met-NH2-(1 mol eq) with visible light at 37ºC for 7 h. Surpris-
ingly, only monofunctional adducts 6a,b and chelate 6c were 
formed, as inferred by HPLC and MS analysis (Figure S-21). No 
evidence for the interaction between the tripeptide and 
photoreleased 1 or adduct 6c was obtained from these experi-
ments. Further investigations will be necessary to determine 
whether other potential biological ligands can form ternary 
adducts with ruthenated DNA as a consequence of in situ irra-
diation with visible light.  
 
Conclusion. In summary, we have described a straightfor-
ward methodology for the conjugation of a photoactivated ru-
thenium(II) arene complex to receptor-binding peptides such as 
a dicarba analogue of octreotide and the RGD sequence. UV-vis 
spectroscopy and NMR data have demonstrated that both con-
jugates are completely stable in aqueous solution in the dark 
but that the corresponding pyridyl-derivatized peptides are se-
lectively photodissociated upon irradiation with visible light, 
providing an elegant and innovative mechanism for the 
activation of such potential anticancer agents. Importantly, the 
release of the aqua complex from the conjugate, namely [(η6-p-
cym)Ru(bpm)(H2O)]
2+, is not influenced by the covalent at-
tachment of the peptides to the pyridine ligand. In addition, 
this reactive species is able to bind a DNA nucleobase model, 9-
ethylguanine, as well as the two guanines in two DNA se-
quences, 5’dCATGGCT and 5’dAGCCATG, as inferred by 
NMR and enzymatic digestion in combination with MS. This 
behavior was reproduced with Phac-His-Gly-Met-linker-
p5’dCATGGCT since two monofunctional adducts on both 
guanine nucleobases were also formed. Surprisingly, when the 
ruthenium-octreotide conjugate was irradiated in the presence 
of both oligonucleotides or the peptide-oligonucleotide hybrid, 
a new ruthenated product involving coordination to the two 
guanines was formed as a consequence of the loss of the p-
cymene ligand. The formation of this adduct with a bidentate 
binding mode is phototriggered from monofunctional adducts 
on guanines, even if they are located far from each other in the 
DNA sequence. Since irradiation will be performed in situ in 
the tumor, the generation of such non-classical adducts might 
have important implications for cellular repair mechanisms. In 
the experiments with Phac-His-Gly-Met-linker-p5’dCATGGCT, 
no interaction was found with the peptide fragment, even in 
the adduct in which p-cymene had been lost, which indicates a 
higher preference of this photoactivated ruthenium(II) complex 
for guanines on DNA (or RNA) over other potential biological 
ligands such as histidine or methionine amino acids. 
To the best of our knowledge, this work provides the first ex-
ample of a potential ruthenium-based anticancer agent with a 
double mechanism of selectivity. First, the receptor-binding 
peptide can act as a “tumour targeting device”, thereby directing 
the ruthenium pro-drug to the cancer cell via specific receptors 
that are overexpressed on the membrane of certain tumoural 
cells. Second, direct irradiation with visible light in the tumor 
will promote photodissociation of the ruthenium aqua com-
plex, [(η6-p-cym)Ru(bpm)(H2O)]2+, from the peptide. Our ex-
periments demonstrate that this reactive species might react 
preferably with DNA compared to proteins and that, under 
irradiation, classical monofunctional ruthenium adducts on 
guanine nucleobases might be transformed into more resistant 
adducts. This dual mechanism of selectivity and activity will not 
only contribute to reducing toxic side-effects associated with 
metal-based anticancer drugs, but also has the potential to pro-
duce novel lesions on DNA and therefore a novel mechanism 
of anticancer activity with a low cross-resistance to other drugs. 
Work is in progress to evaluate the biological activity of the 
conjugates toward several cancer cell lines as well as to extend 
this strategy to delivering other biomolecules and photoactive 
metal complexes. 
 
Experimental Section 
Materials and Methods. Unless otherwise stated, common 
chemicals and solvents (HPLC grade or reagent grade quality) 
were purchased from commercial sources and used without 
further purification. Fmoc-protected amino acids, resins and 
coupling reagents for solid-phase synthesis were obtained from 
Novabiochem, Bachem or Iris Biotech. Milli-Q water was di-
rectly obtained from a Milli-Q system equipped with a 5000-Da 
ultrafiltration cartridge. Solid-phase syntheses were performed 
manually in a polypropylene syringe fitted with a polyethylene 
disc. The syntheses of [(η6-p-cym)Ru(bpm)(Cl)][PF6] and [(η6-p-
cym)Ru(bpm)(H2O)][PF6]2 were carried out following previously 
reported procedures.6  
A) NMR spectroscopy: NMR spectra were recorded at 25ºC on 
a Varian Gemini 200 or 300 MHz and Varian Mercury 400 
MHz spectrometers using deuterated solvents. Tetramethylsi-
lane (TMS) was used as an internal reference (δ 0 ppm) for 1H 
spectra recorded in CDCl3 and the residual signal of the solvent 
(δ 77.16 ppm) for 13C spectra. In the case of irradiation experi-
ments, NMR spectra were acquired on a Bruker AV II 700 
MHz spectrometer and 1H NMR signals were referenced to 
dioxane as an internal reference (δ 3.75 ppm). A standard phase 
sensitive NOESY pulse sequence was employed with 0.8 s mix-
ing time. Solutions of 400 µM 2 and 3 were employed for 
photolysis studies.  
B) Mass spectrometry: High resolution MALDI-TOF mass spec-
tra were recorded on a 4800 Plus MALDI-TOF/TOF spec-
trometer (Applied Biosystems) in the positive mode using 2,4-
dihidroxybenzoic acid as a matrix. ESI mass spectra (ESI-MS) 
were recorded on a Micromass ZQ instrument with a single 
quadrupole detector coupled to an HPLC. High resolution 
electrospray mass spectra (HR ESI-MS) were obtained either on 
a BrukerMaXis UHR-TOF or on an Agilent 1100 LC/MS-TOF 
instrument.  
C) UV-vis absorption spectroscopy: UV-vis absorption spectra 
were recorded on a Cary 50-Bio spectrophotometer using 1-cm 
path-length quartz cuvettes (0.5 mL) and a PTP1 Peltier tem-
perature controller. Spectra were recorded at ca 37ºC in double 
distilled water from 800 to 230 nm, and were processed using 
UV-Winlab software for Windows 95. 200 µM solution of 2 
and 3 were employed for photolysis studies.  
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D) Irradiation experiments: The light source was a Luzchem 
LZC-ICH2 illuminator (photo-reactor) oven using LZC-420 
(blue light) lamps, with no other sources of light filtration. The 
photo-reactor operated at 420 nm (λmax) with temperature con-
troller at 37ºC and power level of ca 1 J cm–2 h–1. The power 
levels were monitored using the appropriate probe window, 
calibrated with an OAI power meter from Optical Associates, 
Inc.  
E) HPLC analysis and purification: Analytical reversed-phase 
HPLC analyses were carried out on a Jupiter Proteo C18 column 
(250 x 4 mm, 5 µm, flow rate: 1 mL/min), using linear gradi-
ents of 0.045% TFA in H2O (solvent A) and 0.036% TFA in 
ACN (solvent B). Purification was carried out on a Jupiter Pro-
teo semipreparative column (250 x 10 mm, 10 µm, flow rate: 4 
mL/min), using linear gradients of 0.1% TFA in H2O (solvent 
A) and 0.1% TFA in ACN (solvent B). HPLC-MS analysis was 
performed using a Micromass ZQ mass spectrometer equipped 
with an electrospray source and a single quadrupole detector 
coupled to a Waters 2695 HPLC (photodiode array detector). 
Elution was performed on a GraceSmart C18 column (150 x 2.1 
mm, 5 µm, flow rate: 0.25 ml/min) with linear gradients of 
H2O and ACN containing both solvents 0.1% formic acid.  
Synthesis of the ruthenium-peptide conjugates 2 and 3. A) 
Octreotide-ruthenium conjugate 2: 8 µmol of the pyridyl-derivatized 
octreotide 4 were dissolved in 800 µL of Milli-Q water and the 
pH was adjusted to 6.5 by adding a few µL of a 10 mM aqueous 
solution of NaOH. The Eppendorf tube was protected from 
light by covering it with aluminium foil and 1.5 mL of a 20 mM 
solution of [(η6-p-cym)Ru(bpm)(H2O)][PF6]2 (3.75 eq) in 
H2O/MeOH 1:1 were added dropwise for 5 min. The reaction 
mixture was kept at 60ºC for 72 h protected from the light. 
Reversed-phase HPLC analysis revealed the formation of a new 
peak (87%) which corresponds to the conjugate 2, as inferred 
by ESI MS. After purification by semipreparative HPLC (gradi-
ent: 20 to 60% in 30 min, Rt= 12.6 min) and lyophilisation, the 
product was obtained as a yellow foam (28% global yield). 
Characterization: Rt= 13.7 min (analytical gradient: 20 to 60% 
in 30 min); HR ESI-MS, positive mode: m/z 820.3584 (calcd 
mass for C82H106N16O14Ru [M]
2+: 820.3559), 547.2400 (calcd 
mass for C82H107N16O14Ru [M+H]
3+: 547.2399). 
B) RGD-ruthenium conjugate 3: 1 µmol of the pyridyl-
derivatized RGD peptide 5 was dissolved in 450 µL of Milli-Q 
water and the pH was adjusted to 6.8 by adding a few µL of a 
10 mM aqueous solution of NaOH. The Eppendorf tube was 
protected from light by covering it with aluminium foil and 1 
mL of a 20 mM solution of [(η6-p-cym)Ru(bpm)(H2O)][PF6]2 (20 
eq) in H2O/MeOH 1:1 was added dropwise over 5 min. The 
reaction mixture was kept at 60ºC for 48 h protected from the 
light. Reversed-HPLC analysis revealed the formation of a new 
peak (65%) which corresponds to the conjugate 3, as inferred 
by ESI MS. After purification by semipreparative HPLC (gradi-
ent: 0 to 40% in 30 min, Rt= 18.2 min) and lyophilisation, the 
product was obtained as a yellow foam (29% global yield). 
Characterization: Rt= 15.3 min (analytical gradient: 0 to 50% in 
30 min); HR ESI-MS, positive mode: m/z 501.6795 (calcd mass 
for [M]2+ C43H59N13O9Ru: 501.6801), 334.7887 (calcd mass for 
C43H60N13O9Ru [M+H]
3+: 334.7893). 
DNA binding studies. A) In situ experiments: The required 
volume of an aqueous solution of conjugate 2 was mixed with 
the required volume of an aqueous solution of the oligonucleo-
tide, 5´dCATGGCT (5 mol eq) or 5´dAGCCATG (1 mol eq), or 
the peptide-oligonucleotide hybrid (1 mol eq), Phac-His-Gly-
Met-linker-p5´dCATGGCT. The solutions were 100 µM in 2. 
Ruthenation reactions were carried out at 37ºC in a quartz 
cuvette under visible light irradiation. The light source was a 
Philips Belgium A3 Master HPI-T Plus 400W visible lamp and a 
1 M aqueous solution of NaNO2 was used as a filter to cut off 
the UV-light and ensure the appropriate wavelength range (> 
400 nm).  
B) DNA binding to pre-irradiated samples: An aqueous solution 
of conjugate 2 (100 µM) was irradiated for 9 h at 37ºC. Then, 
the required volume of an aqueous solution of the oligonucleo-
tide (5 mol eq) or the peptide-oligonucleotide hybrid (1 mol eq) 
was added and the reaction mixture was incubated protected 
from light at 37ºC overnight. 
C) Control experiments with 1: The required volume of a 20 
mM solution of [(η6-p-cym)Ru(bpm)(H2O)][PF6]2 in 
H2O/MeOH 1:1 was mixed with the required volume of an 
aqueous solution of 5´dCATGGCT (5 mol eq) or Phac-His-Gly-
Met-linker-p5´dCATGGCT (1 mol eq). The solutions were 100 
µM in 1. Ruthenation reactions were carried out at room tem-
perature overnight and protected from light.  
D) Analysis and characterization of the ruthenium adducts: The 
evolution of the reactions was monitored by reversed-phase 
HPLC on Kromasil C18 columns (250 x 4.6 mm, 10 µm, flow 
rate: 1 mL/min), using linear gradients of aqueous triethylam-
monium acetate (0.05 M) (solvent A) and ACN/H2O 1:1 (sol-
vent B). Ruthenium adducts were isolated after several HPLC 
runs by using analytical separation conditions. HR MALDI-
TOF MS analysis was carried out in the negative mode using 
2,4,6-trihidroxyacetophenone matrix with ammonium citrate as 
an additive. Enzymatic digestions with 5’- and 3’-exonucleases 
(bovine spleen and snake venom phosphodiesterases, respec-
tively), nuclease S1 and pronase were performed as previously 
described.16  
D.1) Adduct 5´dCATGGCT-[(η6-p-cym)Ru(bpm)]2+ 6a: Rt= 18.3 
min (gradient: 5 to 45% in 30 min). HR ESI-MS, negative mo-
de: m/z 1242.7169 (calcd mass for C86H103N29O41P6Ru [M-4H]
2-: 
1242.7168), m/z 828.1432 (calcd mass for C86H102N29O41P6Ru 
[M-5H]3-: 828.1419), m/z 620.8536 (calcd mass for 
C86H101N29O41P6Ru [M-6H]
4-: 620.8545). MALDI-TOF-MS, 
negative mode: m/z 2486.8 (calcd mass for C86H104N29O41P6Ru 
[M-3H]-: 2486.44), m/z 2352.7 (calcd mass for 
C76H90N29O41P6Ru [M-(p-cym)-3H]
-: 2352.33), m/z 2329.7 (calcd 
mass for C78H98N25O41P6Ru [M-bpm-3H]
-: 2328.38). MALDI-
TOF-MS after digestion with snake venom phosphodiesterase: 
m/z 1759.9 (-pCpT) (calcd mass for C57H65N24O28P4Ru [M-(p-
cym)-3H]-: 1759.24), m/z 1501.8 (-pCpT) (calcd mass for 
C49H61N20O28P4 [M-(p-cym)-Ru-bpm-H]
-: 1501.29). MALDI-TOF-
MS after digestion with bovine spleen phosphodiesterase: m/z 
1580.9 (-CpApTp) (calcd mass for C57H67N19O23P3Ru [M-3H]
-: 
1580.29), m/z 1446.8 (-CpApTp) (calcd mass for 
C47H53N19O23P3Ru [M-(p-cym)-3H]
-: 1446.18), m/z 1422.8 (-
CpApTp) (calcd mass for C49H61N15O23P3Ru [M-bpm-3H]
-: 
1422.23), m/z 1188.7 (-CpApTp) (calcd mass for 
C39H49N15O23P3 [M-(p-cym)-Ru-bpm-H]
-: 1188.24), m/z 859.2 (-
CpApTpGp) (calcd mass for C29H37N10O17P2 [M-(p-cym)-Ru-
bpm-H]-: 859.18).  
D.2) Adduct 5´dCATGGCT-[(η6-p-cym)Ru(bpm)]2+ 6b: Rt= 19.1 
min (gradient: 5 to 45% in 30 min). HR ESI-MS, negative mo-
de: m/z 1242.7126 (calcd mass for C86H103N29O41P6Ru [M-4H]
2-: 
1242.7168), m/z 828.1422 (calcd mass for C86H102N29O41P6Ru 
[M-5H]3-: 828.1419), m/z 620.8560 (calcd mass for 
C86H101N29O41P6Ru [M-6H]
4-: 620.8545). MALDI-TOF-MS, 
negative mode: m/z 2486.0 (calcd mass for C86H104N29O41P6Ru 
[M-3H]-: 2486.44), m/z 2352.9 (calcd mass for 
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C76H90N29O41P6Ru [M-(p-cym)-3H]
-: 2352.33), m/z 2328.9 (calcd 
mass for C78H98N25O41P6Ru [M-bpm-3H]
-: 2328.38). MALDI-
TOF-MS after digestion with snake venom phosphodiesterase: 
m/z 1430.8 (-pGpCpT) (calcd mass for C47H53N19O22P3Ru [M-(p-
cym)-3H]-: 1430.19), m/z 1407.8 (-pGpCpT) (calcd mass for 
C49H61N15O22P3Ru [M-bpm-3H]
-: 1406.24), m/z 1172.7 (-
pGpCpT) (calcd mass for C39H49N15O22P3 [M-(p-cym)-Ru-bpm-
H]-: 1172.24). MALDI-TOF-MS after digestion with bovine 
spleen phosphodiesterase: m/z 1885.1 (-CpAp) (calcd mass for 
C67H80N21O30P4Ru [M-3H]
-: 1884.34), m/z 1750.9 (-CpAp) 
(calcd mass for C57H66N21O30P4Ru [M-(p-cym)-3H]
-: 1750.23), 
m/z 1727.0 (-CpAp) (calcd mass for C59H74N17O30P4Ru [M-bpm-
3H]-: 1726.28), m/z 1492.9 (-CpAp) (calcd mass for 
C49H62N17O30P4 [M-(p-cym)-Ru-bpm-H]
-: 1492.29), m/z 1188.3 (-
CpApTp) (calcd mass for C39H49N15O23P3 [M-(p-cym)-Ru-bpm-H]
-
: 1188.23).  
D.3) Adduct 5´dCATGGCT-[Ru(bpm)]2+ 6c: Rt= 18.6 min (gra-
dient: 5 to 45% in 30 min). HR ESI-MS, negative mode: m/z 
783.4331 (calcd mass for C76H88N29O41P6Ru [M-5H]
3-: 
783.4387), m/z 587.3270 (calcd mass for C76H87N29O41P6Ru [M-
6H]4-: 587.3271). MALDI-TOF-MS, negative mode: m/z 2352.8 
(calcd mass for C76H90N29O41P6Ru [M-3H]
-: 2352.33). MALDI-
TOF-MS after digestion with snake venom phosphodiesterase: 
m/z 1759.9 (-pCpT) (calcd mass for C57H65N24O28P4Ru [M-3H]
-: 
1759.24), m/z 1501.9 (-pCpT) (calcd mass for C49H61N20O28P4 
[M-Ru-bpm-H]-: 1501.29). MALDI-TOF-MS after digestion with 
bovine spleen phosphodiesterase: m/z 1750.8 (-CpAp) (calcd 
mass for C57H66N21O30P4Ru [M-3H]
-: 1750.23), m/z 1492.8 (-
CpAp) (calcd mass for C49H62N17O30P4 [M-Ru-bpm-H]
-: 
1492.29), m/z 1188.3 (-CpApTp) (calcd mass for 
C39H49N15O23P3 [M-(p-cym)-Ru-bpm-H]
-: 1188.23). MALDI-TOF-
MS after digestion with Nuclease S1: m/z 1222.1 (-5’CpApTp, -
3’T) (calcd mass for C37H41N17O19P3Ru [M-3H]
-: 1222.10), m/z 
1526.1 (-5’CpAp, -3’T) (calcd mass for C47H54N19O26P4Ru [M-3H]
-
: 1526.15). 
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ABBREVIATIONS 
ACN, acetonitrile; bpm, 2,2'-bipyrimidine; cym, cymene (1-methyl-
4-(1-methylethyl)benzene); DCM, dichloromethane; DIPC, N,N’-
diisopropylcarbodiimide; DIPEA, N,N-diisopropylethylamine; 
DMF, N,N-dimethylformamide; DsaC, diaminosuberic acid C-
terminus; DsaN, diaminosuberic acid N-terminus; ESI, electrospray 
ionization; EtG, ethylguanine; Fmoc, 9-
fluorenylmethyloxycarbonyl; HATU, (2-(7-Aza-1H-benzotriazole-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HOAt, 1-
hydroxy-7-azabenzotriazole; HOBt, 1-hydroxybenzotriazole; HR, 
high resolution; MALDI-TOF, matrix-assisted laser desorption 
ionization time-of-flight; py: pyridine; TIS, triisopropylsilane; TFA, 
trifluoroacetic acid. 
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